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Abstract
Background: Rapid diagnostic tests (RDTs) for malaria are increasingly being considered for routine use
in Africa. However, many RDTs are available and selecting the ideal test for a particular setting is
challenging. The appropriateness of RDT choice depends in part on patient population and epidemiological
setting, and on decision makers' priorities. The model presented (available online) can be used by decision
makers to evaluate alternative RDTs and assess the circumstances under which their use is justified on
economic grounds.
Methods: An interactive model based on a decision-tree structure and a cost-benefit framework was
designed to compare different diagnostic strategies. Variables included in the model can be modified by
users, including RDT and treatment costs, test accuracies (sensitivity and specificity), probabilities for
developing severe illness, case-fatality rates, and clinician response to negative test results. To illustrate
how the model can be used, a comparison is made of presumptive treatment with two available RDTs, one
detecting histidine-rich protein-2 (HRP2) and one detecting Plasmodium lactate dehydrogenase (pLDH).
Data inputs were obtained from a study comparing the RDTs at seven sites in Uganda.
Results:  Applying the model in the illustrative Ugandan context demonstrates that if only direct
expenditures are considered, the pLDH test is the preferred option for adult patients except in high
transmission settings, while young children are best treated presumptively in all settings. When health
outcomes are considered, the HRP2 test gains an advantage in almost all settings and for all age groups.
Introducing possible adverse consequences of using an antimalarial into the analysis, such as adverse drug
reactions, or the development of resistance, considerably strengthens the case for using RDTs. When the
model is adjusted to account for less than complete adherence to test results, the efficiency of using RDTs
drops sharply.
Conclusion: Model output demonstrates that which test is preferable varies by location, depending on
factors such as malaria transmission intensity and the costs and accuracies of the RDTs under
consideration. Despite the uncertainties and complexities involved, adaptable models such as the one
presented here can serve as a practical tool to assist policy makers in efficient deployment of new
technologies.
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Background
The role of RDTs and decisions in their implementation
In sub-Saharan Africa, management of febrile patients is
typically characterized by over-prescription of antimalar-
ial drugs [1-4], as clinicians often do not have access to, or
do not request, laboratory testing before prescribing anti-
malarials [4,5]. Such practices were accepted, and even
encouraged, when older, more affordable antimalarials
such as chloroquine and sulphadoxine-pyrimethamine
were effective. However, now that parasite resistance
necessitates the introduction of new regimens such as
artemisinin combination therapies (ACTs) [6-9], the strat-
egy of presumptive treatment has become more problem-
atic, as the new drugs are significantly more expensive and
their safety profiles are not fully characterized. Use of
rapid diagnostic tests (RDTs) to guide antimalarial ther-
apy is increasingly advocated as a potentially safe and
cost-effective strategy for fever case management [10-13].
With an increasingly large number of RDTs available on
the market, decision-makers must consider a number of
factors in determining which diagnostic test is likely to be
most appropriate in a particular context. Some of these
relate to qualities of the RDT itself, such as target antigen,
sensitivity, specificity, shelf-life, heat sensitivity and cost.
Other factors relate to the demographic and epidemiolog-
ical circumstances of areas where the tests are to be
deployed. Some data are available, for example from field
studies of RDT accuracy in various settings, but data are
lacking for other critical parameters that are likely to influ-
ence the overall costs and benefits of implementing RDTs.
Even where data are available, many of these factors vary
even within a single country or region, presenting a com-
plicated picture to decision-makers.
The availability, performance and prices of diagnostic
tests and treatments can vary widely over time and loca-
tion, as do transmission intensity and host immunity. It is
unlikely therefore that any RDT would maintain its
advantage indefinitely or across all endemic areas. Simi-
larly, economic evaluations of an RDT carried out in one
setting may not be relevant in others, or lose their validity
within a relatively short time as epidemiological patterns
and the characteristics of competitor tests changes. For
these reasons, policy makers might benefit from decision
aids that incorporate available data and parameter esti-
mates for factors that are variable, to provide up-to-date
recommendations relevant to their circumstances.
Factors for consideration in choice of RDT
The presumptive treatment of fever episodes as malaria
results in significant overuse of antimalarials and delays
diagnosis of other illnesses [14-16]. Therefore, an impor-
tant potential gain from introducing a new diagnostic test
is in reducing the proportion of febrile patients who
receive unnecessary antimalarial treatment. This safely
reduces the cost of giving unnecessary antimalarials, and
may help to avert morbidity associated with untreated
non-malaria illness. An ideal RDT should therefore have
high specificity to avoid false-positive results that would
prompt unnecessary antimalarial treatment. At the same
time, it is critical that an RDT must have high sensitivity to
ensure that true cases of malaria are detected and treated
appropriately.
In reality, improved sensitivity often comes at the expense
of reduced specificity, and vice versa; however, it is diffi-
cult to weigh the implications of this trade-off for an indi-
vidual patient or for public health, as they are often not
directly comparable [17]. Mistakenly diagnosing a patient
as uninfected (a false negative) may have more serious
clinical consequences than mistakenly diagnosing a
patient as infected (a false positive), but this will not
always be true. However withholding antibiotics from a
malaria test-negative individual because of an assumption
the illness is due to malaria may lead to treatable bacterial
disease progressing to become potentially life-threaten-
ing. Extensive overuse of antimalarials is also likely to
come at a considerable cost over the longer term due to
increased drug pressure leading to possible development
of drug resistant parasite strains [2].
The trade-off in sensitivity and specificity is apparent in
the reported accuracies of the two main classes of RDTs
which currently appear most suitable for clinical use,
detecting either histidine-rich protein-2 (HRP2) or Plas-
modium lactate dehydrogenase (pLDH). HRP2 based
assays have shown good sensitivity in a variety of field set-
tings, and are increasingly advocated where reliable
microscopy is not available [11,18]. Their potential disad-
vantage however, is persistence of detectable circulating
antigen for up to several weeks after parasites have been
eradicated [19-21], which may limit the usefulness of
HRP2-based assays in areas of high malaria transmission.
pLDH-based RDTs appear to be less sensitive but are more
specific than HRP2 ones, as the antigen is rapidly cleared
from the bloodstream [22-24]. HRP2- and pLDH-based
tests also differ in the parasite species they detect: the
HRP2 test detects only Plasmodium falciparum, while the
pLDH test detects all four human malaria species.
For two main reasons, evaluations of diagnostic tests
should also account for important differences in malaria
epidemiology and population characteristics. Firstly,
transmission intensity determines prevalence of parasitae-
mia and therefore, the probability of a test result being
correct (the positive and negative predictive values). In
many areas parasite prevalence varies through the year
due to seasonal fluctuations in transmission intensity.
Secondly, in high transmission areas the populationMalaria Journal 2008, 7:21 http://www.malariajournal.com/content/7/1/21
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develops partial immunity with age [25]. An adult in a
high transmission area, for instance, is more likely to be
parasitaemic, but much less likely to develop severe
malaria. A child in a low transmission area, on the other
hand, is less likely to be parasitaemic but more likely to
develop severe malaria once infected. The implications
and benefit of using an RDT in each setting therefore differ
[10,26,27].
Alongside the benefits of correct use of antimalarials, as
for any medication, there are also possible negative conse-
quences. The "harm of treatment" for an antimalarial or
antibiotic includes the potential for drug toxicity, the con-
tribution to the development of parasite (or bacterial)
resistance, and the cost of the use of scarce resources [11].
Evaluations that account for these consequences can pro-
vide more comprehensive estimates of the real costs and
benefits of various diagnostic strategies than those focus-
ing only on immediate implications for management of a
single fever episode.
This paper presents a model designed to incorporate local
and current data and parameter estimates to assist stake-
holders in identifying the most efficient tests and case
management strategies. The aim was to develop a model
that can be adapted to varied settings and RDTs, rather
than to determine RDT cost-effectiveness in a generalized
manner. The model expands on other available models,
including one that compares the use of RDTs with micro-
scopy and presumptive treatment [27], and data that dem-
onstrate the importance of clinician response to test
results [28]. The model presented here broadens the range
of factors included in the analysis and also provides users
with greater ability to explore policy options.
Use of the model is demonstrated here by comparing pre-
sumptive treatment with two RDTs proposed for deploy-
ment in peripheral outpatient departments in Uganda.
Methods
The model was designed to amalgamate the costs and con-
sequences of diagnosing and treating patients according
to results of either of the proposed RDTs or by presump-
tive treatment. The model was then populated with sam-
ple data from field studies in Uganda to illustrate its
function and limitations, and to demonstrate the effect of
changes in each variable on model output. While the data
and output are relevant to these particular settings, they
are presented here only for the purpose of illustrating use
of the model, not as generalizable policy recommenda-
tions. Decision makers will want to review model param-
eters and modify these to their own circumstances where
appropriate.
The model structure
The model is based on a decision-tree structure and cost-
benefit framework, incorporating consequences of diag-
nosis and treatment to estimate the total costs, represent-
ing both expenditure and outcomes, for each of the tests.
Strategies compared in the model include case manage-
ment based on the results of two diagnostic tests, or pre-
sumptive treatment without a confirmed diagnosis.
Monetary values were assigned to consequences of diag-
nosis and treatment, incorporating costs of tests, medica-
tions and inpatient care, and a cost representing the value
of life years lost due to incorrect diagnosis and treatment.
As both costs and consequences of the different strategies
are expressed in monetary terms, these are differentiated
in the text by referring to either 'direct costs' to describe
financial expenditures alone, or to 'total costs' where both
financial expenditures and consequences in terms of value
of life years lost are included. The option that incurs the
lowest total cost is considered the most efficient.
Assignment of monetary values to health outcomes
The probability of death occurring was determined using
estimates for the likelihood of untreated malaria and
other febrile illnesses becoming severe, and subsequent
case fatality rates. These were determined using expert
opinion due to lack of clinical data. Different probabili-
ties were assigned to different age groups and transmis-
sion intensities, as detailed in Table 1.
Table 1: Transition probabilities used in the model. NMFI – Non malarial febrile illness. CFR – Case fatality rate.
Probability untreated malaria becomes severe Age group Source
Transmission intensity Under 5 5 to 10 10+
Low 0.075 0.05 0.01 [25, 32, 41]; supplemented by expert opinion (Chris Whitty, 
Hugh Reyburn)
Medium 0.075 0.01 0.004
High 0.075 0.01 0.0015
CFR severe malaria 0.2 0.2 0.2
Probability untreated NMFI becomes severe 0.01 0.005 0.010
CFR NMFI 0.1 0.20 0.30Malaria Journal 2008, 7:21 http://www.malariajournal.com/content/7/1/21
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The value assigned to a year of life lost (YLL) was initially
set at $150, based on guidance from WHO for a threshold
below which averting the loss of a disability adjusted life
year (DALY) is considered cost-effective [29]. An alterna-
tive method used to value a YLL is to multiply per capita
gross national income (GNI) by three, as discussed in a
report by the WHO Commission on Macroeconomics and
Health [30,31]. Results are presented for both values.
Costs were also assigned to the potential negative conse-
quences of using antimalarials and antibiotics, or the
'harm of treatment'. The initial input used was the only
current available estimate for the harm of treatment
incurred by the use of antimalarials, that for every 200
treatments currently given, one life will be lost at some
time in the future due to allergic reactions, development
of drug resistance, use of scarce resources, and inappropri-
ate treatment of other illnesses [11]. The baseline estimate
for the harm of treatment with antibiotics was set equal to
that of antimalarials. Recognizing the uncertainty around
these estimates, the effects of variation in these values can
also be explored by the user.
The model also accommodates the possibility that clini-
cians might continue to prescribe antimalarials in the face
of negative test results. The values used in generating the
results presented in this paper appear in Table 2. Figure 1
illustrates the possible outcomes and related costs for each
diagnostic approach.
The model interface
The user interface allows for variation of input parame-
ters, making the model adaptable to different antimalarial
and RDT costs, and to different test accuracies (Figure 2).
The interface also enables the user to vary estimates for
key parameters with strong elements of uncertainty. These
include the probability of developing severe illness by age
and transmission intensity, the case fatality rates for
malaria and non-malarial febrile illness, and the probabil-
ity that clinicians adhere to test results.
The user can also choose the perspective of the analysis.
Taking the provider financial perspective considers only
direct costs of tests and treatment. Alternatively the value
of years of life lost to patients due to incorrect diagnosis
can be added to the analysis and varied to capture imme-
diate health benefits for the patients. Finally, a societal
Decision tree structure Figure 1
Decision tree structure. Patient progression and associated costs in a decision tree simulating the management of febrile 
patients. CFR – case fatality rate.Malaria Journal 2008, 7:21 http://www.malariajournal.com/content/7/1/21
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Table 2: Initial parameter estimates used in the model
Parameter Base estimate and alternatives Source
Costs:
ACT $1.8 (adult dose) Uganda MoH
Antibiotic $0.4 (adult dose) Primary data – Joint Medical Store
pLDH RDT $.51 Manufacturer
HRP2 RDT $.55 Manufacturer
Harm of treatment with ACT (or antibiotic) Every 200/2000 ACT doses currently used result in the loss of 
one statistical life
[11]
Inpatient care severe malaria $12 Primary data, Kisiizi Hospital
Inpatient care severe NMFI $20
Accuracies:
pLDH sensitivity 77.1% Primary trial data
pLDH specificity 98.4% Primary trial data
HRP2 sensitivity 98.8% Primary trial data
HRP2 specificity 87.0% Primary trial data
Illness progression probabilities:
Adherence Full adherence -100% Variable in model
Year of Life Lost (YLL) $150, $840 [29-31]
The user interface Figure 2
The user interface. RDT and drug costs, and test accuracies can be accessed and changed using the assigned button on the 
left hand panel, as can the probabilities of developing severe illness and case fatality rates. Other parameters can be adjusted or 
excluded using scroll bars on the left panel. The updated results appear on the right hand side. The bars in the top right panel 
show the total cost for each RDT by varying levels of prevalence, and the trendline depicts the costs for presumptive treat-
ment. The bottom graph displays the relative cost savings for each of the RDTs using presumptive treatment as a baseline, 
again by prevalence level. PT – presumptive treatmentMalaria Journal 2008, 7:21 http://www.malariajournal.com/content/7/1/21
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perspective can be taken, with the incorporation of the
harm of treatment factor.
The model output is displayed on two graphs reflecting
the difference in total costs in both absolute and relative
terms, across three transmission intensities, defined by
prevalence of parasitaemia amongst febrile patients
[28,32]. Low transmission is characterized by a prevalence
of 3% parasitaemia, 30% in medium, and 70% in high.
This allows users to view the most appropriate RDT with
respect to regional and seasonal variation in transmission
intensity. In the top panel of Figure 2, the trendline repre-
sents the total cost in US$ of presumptive treatment in
absolute terms, while each set of bars is the cost for either
RDT at each transmission intensity. Where the bars fall
below the trendline, use of the RDT would, therefore, be
more efficient than presumptive treatment. In the lower
panel the results are displayed in relative terms, using pre-
sumptive treatment as the baseline, so the bars represent
the percentage by which RDTs are more efficient than pre-
sumptive treatment. Both graphs are included as in some
cases the difference in relative terms might seem small,
but is large in absolute terms, and vice versa.
The model was designed using Microsoft Excel® 2002 and
macros were written with Microsoft Visual Basic® 6.3.
RDTs under consideration
The two RDTs evaluated for illustrative purposes in this
report are Paracheck® (Orchid Biochemicals Systems Goa,
India) detecting HRP2 antigens, and Parabank® (Zephyr
Biomedicals, Goa, India) detecting pLDH antigens. The
results are not generalisable to other settings for either the
specific tests or the class of tests; these are an illustration
of the uses of the model for policymakers from a particu-
lar setting. The data on RDT accuracy were obtained in
clinical evaluations at sites with varied malaria epidemiol-
ogy around Uganda, as has been described elsewhere [33].
Briefly, at each site, 1,000 consecutive outpatients referred
to the laboratory for malaria screening, according to the
usual standard of care at the health centres, were studied.
For all samples where an RDT result was discordant with
the microscopy result, polymerase chain reaction (PCR)
was performed to confirm the presence or absence of par-
asitaemia. Sensitivity and specificity for each RDT were
then calculated using PCR-corrected expert microscopy as
the gold standard. Malaria prevalence in symptomatic
patients at each site was defined as the proportion of par-
asitaemic patients according to the gold standard, and was
assumed to be an indication of transmission intensity
[34].
RDT and treatment costs
Treatment was assumed to be with artemether-lumefan-
trine (Coartem®), Uganda's recommended first-line treat-
ment for uncomplicated malaria. Treatment costs for
ACTs and antibiotics were determined by patient age: the
cost of a dose for a child under five years of age was
assumed to be one third of that for an adult, while for chil-
dren aged 5 to 14 years the value used was two thirds of
an adult dose. This corresponds with the figures provided
by the Uganda Ministry of Health (Dr Fred Kato, Malaria
Control Programme, personal communication, 27 April
2007). RDT costs were obtained from the manufacturer
and incorporated an additional 15% on top of purchase
price for transport and wastage [10]. Direct costs of inpa-
tient care for patients with severe illness were estimated
using primary data from Kisiizi Hospital in southwest
Uganda.
Results
To demonstrate the structure and functions of the model,
sample outputs are presented in a step-wise fashion,
beginning with direct diagnostic and treatment costs
alone. This is followed by the inclusion of patient health
outcomes using the estimated values for YLL. The impact
of varying levels of prescriber adherence to RDT results is
then explored. The model output becomes fully compre-
hensive when finally the estimates of harm of treatment
are incorporated. The sensitivity of the results to changes
in each of the input parameters is presented as they are
introduced. For simplicity, only absolute and not relative
costs for each strategy are presented.
Direct cost comparison
For patients under five years of age the current cost of ACT
is only marginally more expensive ($0.02) than either
RDT. Therefore, if health outcomes are excluded from the
analysis, presumptive treatment is the preferred option
across almost all settings for this age group (Figure 3a).
For patients aged five to 14 years, use of either RDT is less
costly in low and medium transmission intensities, and
roughly equal in the high one (result not shown). For
adults both RDTs, and particularly the pLDH test, are less
costly in all settings (Figure 3b).
Considering only direct expenditure excludes important
factors. For example, the advantage of the pLDH test is
explained in part by its lower sensitivity, resulting in fewer
antimalarials being prescribed for true cases of malaria
and, therefore, a lower expenditure. To capture the full
cost of these untreated malaria cases in the model, the
value of years of life lost due to incorrect diagnosis and
treatment must be incorporated.
Introducing the value of YLL
Initially, a baseline value of $150 for a YLL was used. For
patients under five years of age, the introduction of this
value provides both RDTs with an advantage at the low
transmission setting; at higher transmission intensitiesMalaria Journal 2008, 7:21 http://www.malariajournal.com/content/7/1/21
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this advantage is maintained by the HRP2 test, although
decreasingly so as transmission increases. Use of the
pLDH test is least efficient, particularly in high-transmis-
sion areas, due primarily to its lower sensitivity and con-
sequent failure to diagnose and treat true malaria (Figure
4a). When the value of a YLL is increased to $840 (three
times Ugandan GNI per capita) [35], there is a modest fur-
ther increase in the benefit of using the HRP2 test.
For older children, the HRP2 test has a small advantage
over the pLDH test across all three settings, with the pLDH
test being more costly than presumptive treatment at the
high transmission intensity. For adults both RDTs are
more efficient than presumptive treatment across all set-
tings (Figure 4b), with substantial cost savings at sites with
lower transmission.
Adherence
Results so far assume that clinicians prescribe treatment
that are consistent with test results in prescribing treat-
ments. However, consistent responses cannot be assumed
given evidence from many areas showing that antimalar-
ials are often prescribed even if test results are negative,
and the degree of consistency affects comparisons [4,26].
For children aged five to 14 years for instance, the advan-
tage gained by using the HRP2 test is lost once adherence
falls below approximately 65%, and presumptive treat-
ment becomes the preferred option.
Harm of treatment
When the harm of treatment associated with over-pre-
scription of antimalarials is included, results change con-
siderably in favour of either RDT. The baseline estimate
Results with direct costs alone Figure 3
Results with direct costs alone. Costs of diagnosis and treatment for children under 5 (left) and for adults (right). For chil-
dren the consideration of direct costs alone implies that presumptive treatment is the preferred option across all prevalences. 
For adults the RDT bars remain below the presumptive treatment trendline, indicating that the use of RDTs is less costly than 
presumptive treatment. PT – presumptive treatment
Results incorporating the value of health outcomes Figure 4
Results incorporating the value of health outcomes. Costs for children under 5 years (left) and adults (right), incorpo-
rating the value of life years lost. For young children presumptive treatment maintains a slight advantage over the HRP2 test, 
while the pLDH test would incur significantly higher costs, particularly at higher transmission intensity. For adults either test 
would be slightly more efficient than presumptive treatment, with a slight advantage to the HRP2 test up to very high preva-
lences. PT – presumptive treatmentMalaria Journal 2008, 7:21 http://www.malariajournal.com/content/7/1/21
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implies that for every 200 ACTs given, one statistical life is
lost in the future [11]. Figure 5a demonstrates that for
children under five years, where previously presumptive
treatment was the preferred option, when the harm of
treatment is added to the analysis the use of RDTs is sub-
stantially more efficient across all settings. Recognizing
the uncertainty around this value, a second value of 2,000
was arbitrarily chosen to observe the sensitivity of results
to a lower estimate of harm of treatment. Even with much
lower estimate of harm of treatment, the HRP2 test
remained the most efficient choice (Figure 5b). At the
medium transmission intensity, the harm of treatment
value would have to be above 7,000 (i.e. prescription of
7,000 antimalarials equates to one statistical death)
before presumptive treatment again becomes the more
efficient option.
For older patients results are similar, with almost no dif-
ference between the two RDTs – both being 30% to 50%
more efficient than presumptive treatment at the lower
transmission intensities. This advantage was maintained
by the HRP2 test in areas of high transmission as well.
This result was robust to reduction in the value of the
harm of treatment.
Discussion
Adaptable economic models as decision support tools
ACTs are a valuable resource and use of RDTs to target
therapy is likely to be preferable to presumptive treatment
in certain settings. A variety of RDTs are available, each
with potential advantages and disadvantages, and decid-
ing on the appropriate diagnostic approach for a given set-
ting can be challenging. This paper presents a model
which can compare different rapid diagnostic tests with
one another and presumptive treatment. Policymakers
can vary the parameters depending on local conditions,
new data, and their own opinions where data are not
available. The model demonstrates that which diagnostic
strategy or test is likely to be cost-effective depends on set-
ting, and perspective.
This model aims to be useful to stakeholders and decision
makers in a number of ways. Firstly, by demonstrating the
variation in performance by patient age and transmission
intensity, policies may be better targeted to the local envi-
ronments and patient populations. While it may not be
feasible in all cases to implement policies that vary by
region or population, as this may add costs and complex-
ities to the implementation process, considering the pos-
sible variation will provide more accurate and nuanced
data to inform the development of national strategies.
Secondly, the interactive nature of the model allows poli-
cymakers to select which input parameters are relevant,
and to use values that reflect the local settings. Thirdly, the
model can be used to identify influential parameters for
which values are uncertain, and to indicate the need for
investing in further research to derive more accurate esti-
mates.
Models can appear to make highly complex policy dilem-
mas overly simplistic, but despite all the uncertainties and
complexities, decisions regarding the use of RDTs are
being made, often using little more than intuitive inclina-
tion in the absence of better data. Models such as this
assist in seeking to synthesise a large array of parameters
that should all enter the decision making process.
Decision and policy implications in the Ugandan context
Using the RDT accuracy data available for Uganda as an
illustration, the model suggests that at current RDT and
ACT prices, use of the illustrative HRP2 RDT would be
appropriate across most endemic settings and patient age
groups. However, the results of the model depend to a
great extent on whether factors such as the harm of treat-
Results with the harm of treatment included Figure 5
Results with the harm of treatment included. Total costs for children with a high (left) and low (right) estimate of harm 
of treatment associated with provision of antimalarials and antibiotics. Even with a very conservative estimate of the potential 
harm of treatment, the HRP2 test maintains an advantage across all prevalences. PT – presumptive treatmentMalaria Journal 2008, 7:21 http://www.malariajournal.com/content/7/1/21
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ment and the probability of clinicians adhering to results
are included in the analysis.
If the model is set to exclude the harm of treatment, as
ACTs drop in price, presumptive treatment becomes justi-
fied for younger children, and the advantage of RDTs for
older patients is greatly reduced. Results of the model
highlight to policy makers the importance of encouraging
clinicians to adhere to negative test results, if RDTs are to
be an efficient use of resources.
Limitations
For some parameters in this model, such as harm of treat-
ment, only rough estimates are available, and in many set-
tings, local data for other parameters affecting RDT choice
are unavailable. However, use of reasonable estimates and
exploration of the effects of their variation in the model
may provide a useful guide for decisions on RDT imple-
mentation. For purposes of illustration the model is ini-
tially populated here with current best estimates, as is the
case in standard evaluations. With use of the model, users
may modify these with local data where available, to tailor
results as far as is possible to their own circumstances.
Two factors that were not accounted for in the model are
drug efficacy, and the quality of life during illness or due
to neurological sequelae. These were excluded assuming
that they would have equal impact on all arms, and there-
fore would not alter decision recommendations. Shelf life
of RDTs and stability at high temperatures are two opera-
tional factors that cannot be modelled reliably given cur-
rent knowledge, but which may need to be taken into
account in local settings in addition to predictive value
and cost-effectiveness.
The difficulties surrounding the assignment of monetary
values for years of life lost has been discussed extensively
in the literature [30,36-39]. The values used in this analy-
sis were derived from two commonly used methods – one
representing a threshold for willingness to pay for a DALY
averted derived by the WHO [29], and the other reflecting
productivity costs by using a multiple of GNI [30,31]. In
this analysis these measures have been used to value YLLs,
which as opposed to DALYs do not account for a quality
of life dimension. This was considered acceptable as in the
context of malaria, the quality of life component is
assumed to be of marginal importance in comparison to
the loss of life years [40], so the two measures are almost
equivalent.
The parameter surrounded with most uncertainty is the
potential harm of treatment with antimalarials (or any
other medication). Quantifying this requires challenging
assessments such as the probability of toxicity, and the
relationship of quantities of ACTs used to development of
resistance, which can make the estimates appear rather
arbitrary. The baseline estimate used is the only one cur-
rently available in the literature. Given this uncertainty,
this parameter was varied by one order of magnitude to
test its robustness, followed by a threshold analysis to
determine the point where presumptive treatment again
becomes more efficient.
Despite the difficulties in estimating this parameter, it is
important that whatever estimates are available be
accounted for in a decision model. Excluding a value for
potential harm of treatment essentially can equate to say-
ing the long term costs associated with widespread use of
antibiotics or antimalarials are zero. The model allows the
user to observe how changes in these values influence
decision recommendations. The assignment of an equal
cost to antibiotics was done on expert opinion, although
users are encouraged to question this and where appropri-
ate enter their own estimates in the model.
Conclusion
This paper presents a model that explores important
parameters influencing RDT costs and benefits, that can
be used by decision makers to evaluate alternative RDTs
and assess the circumstances under which their use may
be justified on economic grounds. It demonstrates the
importance of the epidemiological setting in determining
which test is most appropriate. The model is suitable for
use with local data concerning test accuracies and costs of
diagnostics and treatments, and allows policy makers and
other stakeholders to use their own estimates for a variety
of other parameters. Sample data are used to demonstrate
how the model can be used to provide recommendations
relevant to RDT implementation in the Ugandan context.
The question of which diagnostic approach is most cost-
effective does not have a single correct answer. This paper
demonstrates how in a diverse and rapidly evolving envi-
ronment, adaptable and responsive models can offer
guidance to encourage the most efficient deployment of
new technologies.
Model availability and requirements
Project name: RDT Decision Support Model
Project home page: http://www.hefp.lshtm.ac.uk/publica
tions
Operating system(s): All systems supporting Microsoft
Office® software with Macros enabled in Excel
Programming language: Microsoft Excel ®  2002 and
Microsoft Visual Basic® 6.3Malaria Journal 2008, 7:21 http://www.malariajournal.com/content/7/1/21
Page 10 of 11
(page number not for citation purposes)
Authors' contributions
YL designed the model; HH and YL wrote the initial man-
uscript draft; all authors contributed equally to the final
content.
Acknowledgements
We would like to thank all patients, their families and staff at the trial sites, 
and Dr Robert Sekimpi at the Kihihi health facility in particular. We thank 
Dr Fred Kato and Dr Hugh Reyburn for their expert opinions on parameter 
estimates, and Dr Tonny Tumwesigye at Kisiizi Hospital for his assistance 
with evaluating inpatient care. We are grateful to Dr Adoke Yeka, Dr Hasifa 
Bukirwa, Dr Arthur Mpimbaza, Kambale Wilson, and the rest of the staff at 
the MU-UCSF Malaria Research Collaboration and Uganda Malaria Surveil-
lance Project for their assistance.
YL is supported by a Medical Research Council Doctoral Training Award. 
HH is supported by the National Institutes of Health, USA, grant award K23 
AI065457-01. CJMW is supported by the Gates Malaria Partnership. SGS 
and AM are supported by the London School of Hygiene & Tropical Medi-
cine. None of the funding agencies had any role in the preparation or sub-
mission of this manuscript.
References
1. Amexo M, Tolhurst R, Barnish G, Bates I: Malaria misdiagnosis:
effects on the poor and vulnerable.  Lancet 2004, 364:1896-1898.
2. Bloland PB, Kachur SP, Williams HA: Trends in antimalarial drug
deployment in sub-Saharan Africa.  J Exp Biol 2003, 206(Pt
21):3761-3769.
3. Nosten F, Ashley E: The detection and treatment of Plasmo-
dium falciparum malaria: Time for change.  J Postgrad Med
2004, 50(1):35-39.
4. Reyburn H, Mbakilwa H, Mwangi R, Mwerinde O, Olomi R, Drakeley
C, Whitty CJ: Rapid diagnostic tests compared with malaria
microscopy for guiding outpatient treatment of febrile ill-
ness in Tanzania: randomised trial.  Bmj 2007, 334(7590):403.
5. Hamer DH, Ndhlovu M, Zurovac D, Fox M, Yeboah-Antwi K, Chanda
P, Sipilinyambe N, Simon JL, Snow RW: Improved diagnostic test-
ing and malaria treatment practices in Zambia.  Jama 2007,
297(20):2227-2231.
6. Agnamey P, Brasseur P, Cisse M, Gaye O, Dumoulin J, Rigal J, Taylor
WR, Olliaro P: Economic evaluation of a policy change from
single-agent treatment for suspected malaria to artesunate-
amodiaquine for microscopically confirmed uncomplicated
falciparum malaria in the Oussouye District of south-west-
ern Senegal.  Trop Med Int Health 2005, 10(9):926-933.
7. Barnes KI, Durrheim DN, Little F, Jackson A, Mehta U, Allen E,
Dlamini SS, Tsoka J, Bredenkamp B, Mthembu DJ, et al.: Effect of
artemether-lumefantrine policy and improved vector con-
trol on malaria burden in KwaZulu-Natal, South Africa.  PLoS
Med 2005, 2(11):e330.
8. Zurovac D, Ndhlovu M, Sipilanyambe N, Chanda P, Hamer DH,
Simon JL, Snow RW: Paediatric malaria case-management with
artemether-lumefantrine in Zambia: a repeat cross-sec-
tional study.  Malar J 2007, 6:31.
9. Malik EM, Mohamed TA, Elmardi KA, Mowien RM, Elhassan AH, Ela-
min SB, Mannan AA, Ahmed ES: From chloroquine to artemisi-
nin-based combination therapy: the Sudanese experience.
Malar J 2006, 5:65.
10. Lubell Y, Reyburn H, Mbakilwa H, Mwangi R, Chonya S, Whitty CJ,
Mills A: The cost-effectiveness of parasitological diagnosis for
malaria-suspected patients in an era of combination therapy.
Am J Trop Med Hyg 2007, 77(6):128-132.
11. Rafael ME, Taylor T, Magill A, Lim YW, Girosi F, Allan R: Reducing
the burden of childhood malaria in Africa: the role of
improved diagnostics.  Nature 2006, 444(Suppl 1):39-48.
12. Shillcutt SD, Morel CM, Goodman C, Coleman GC, Bell D, Whitty CJ,
Mills AJ: Cost-effectiveness of malaria diagnostic methods in
sub-Saharan Africa in an era of combination therapy.  Bull
World Health Organ 2007 in press.
13. Mulligan J, Morel C, Mills A: The Cost-Effectiveness of Malaria
Control Interventions.  In DCP2 Working paper PROJECT DCP;
2005. 
14. Chandramohan D, Jaffar S, Greenwood B: Use of clinical algo-
rithms for diagnosing malaria.  Trop Med Int Health 2002,
7(1):45-52.
15. Ndyomugyenyi R, Magnussen P, Clarke S: Diagnosis and treat-
ment of malaria in peripheral health facilities in Uganda:
findings from an area of low transmission in south-western
Uganda.  Malar J 2007, 6:39.
16. Olivar M, Develoux M, Chegou Abari A, Loutan L: Presumptive
diagnosis of malaria results in a significant risk of mistreat-
ment of children in urban Sahel.  Trans R Soc Trop Med Hyg 1991,
85(6):729-730.
17. Girosi F, Rafael ME, Aledorat JE, Lim YW, Boer R, Ricci K, Shea M,
Keeler EB: Determining the Priority Global Health Needs and
Quantifying the Health Benefits Resulting From the Intro-
duction of New Diagnostics in the Developing World.  In
RAND Health RAND; 2006. 
18. Bell D: Malaria rapid diagnostic tests: one size may not fit all.
Clin Microbiol Rev 2002, 15(4):771. discussion 771–772.
19. Mayxay M, Pukrittayakamee S, Chotivanich K, Looareesuwan S,
White NJ: Persistence of Plasmodium falciparum HRP-2 in
successfully treated acute falciparum malaria.  Trans R Soc Trop
Med Hyg 2001, 95(2):179-182.
20. Singh N, Saxena A, Sharma VP: Usefulness of an inexpensive,
Paracheck test in detecting asymptomatic infectious reser-
voir of Plasmodium falciparum during dry season in an inac-
cessible terrain in Central India.  J Infect 2002, 45(3):165-168.
21. Tjitra E, Suprianto S, Dyer ME, Currie BJ, Anstey NM: Detection of
histidine rich protein 2 and panmalarial ICT Malaria Pf/Pv
test antigens after chloroquine treatment of uncomplicated
falciparum malaria does not reliably predict treatment out-
come in eastern Indonesia.  Am J Trop Med Hyg 2001,
65(5):593-598.
22. Moody A, Hunt-Cooke A, Gabbett E, Chiodini P: Performance of
the OptiMAL malaria antigen capture dipstick for malaria
diagnosis and treatment monitoring at the Hospital for
Tropical Diseases, London.  Br J Haematol 2000, 109(4):891-894.
23. Piper R, Lebras J, Wentworth L, Hunt-Cooke A, Houze S, Chiodini P,
Makler M: Immunocapture diagnostic assays for malaria using
Plasmodium lactate dehydrogenase (pLDH).  Am J Trop Med
Hyg 1999, 60(1):109-118.
24. Swarthout TD, Counihan H, Senga RK, van den Broek I: Paracheck-
Pf accuracy and recently treated Plasmodium falciparum
infections: is there a risk of over-diagnosis?  Malar J 2007, 6:58.
25. Snow RW: The burden of malaria: understanding the balance
between immunity, public health and control.  J Med Microbiol
2000, 49(12):1053-1055.
26. Zurovac D, Midia B, Ochola SA, English M, Snow RW: Microscopy
and outpatient malaria case management among older chil-
dren and adults in Kenya.  Trop Med Int Health 2006,
11(4):432-440.
27. Shillcutt S, Morel C, Goodman C, Coleman P, Bombardo C, Whitty
CJ, Mills A, Bretas G, Bell D: Assessing RDT Cost-Effectiveness.
WHO; 2007. 
28. Lubell Y, Reyburn H, Mbakilwa H, Mwangi R, Chonya S, Whitty CJ,
Mills A: The impact of response to the results of diagnostic
tests for malaria: cost-benefit analysis.  Bmj 2008, 336:202-205.
29. WHO CHOICE – CHoosing Interventions that are Cost
Effective   [http://www.who.int/choice/en]
30. Evans DB, (ed): Perspective Paper 2.1.  Cambridge: Cambridge
University Press; 2004. 
31. Sachs J: Macroeconomics and health: Investing in health for
economic development.  Geneva: World Health Organization;
2002. 
32. Marsh K, Snow RW: Malaria transmission and morbidity.  Par-
assitologia 1999, 41(1–3):241-246.
33. Hopkins H, Bebell L, Kambale W, Dokomajilar C, Rosenthal PJ, Dor-
sey G: Rapid Diagnostic Tests for Malaria at Sites of Varied
Transmission Intensity in Uganda.  JID  in press.
34. Bruce-Chwatt LJ: Essential Malariology.  4th edition. Hodder
Arnold; 2002. 
35. World Bank: GNI per capita 2005, Atlas method and PPP.
World Bank; 2007. Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Malaria Journal 2008, 7:21 http://www.malariajournal.com/content/7/1/21
Page 11 of 11
(page number not for citation purposes)
36. Drummond MF, O'Brien B, Stoddart GL, Torrance GW, Sculpher MJ:
Methods for the Economic Evaluation of Health Care Pro-
grammes.  Third edition. Oxford University Press; 2005. 
37. Phelps CE, Mushlin AI: On the (near) equivalence of cost-effec-
tiveness and cost-benefit analyses.  Int J Technol Assess Health
Care 1991, 7:12.
38. Gafni A, Birch S: Incremental cost-effectiveness ratios (ICERs):
the silence of the lambda.  Soc Sci Med 2006, 62(9):2091-2100.
39. Mills A, Shillcutt SD, (eds): Communicable Diseases.  Cambridge:
Cambridge University Press; 2004. 
40. Goodman C, Mutemi W, Baya E, Willetts A, Marsh V: The cost-
effectiveness of improving malaria home management:
shopkeeper training in rural Kenya.  Health Policy Plan 2006,
21(4):275-288.
41. Molineaux L, Muir DA, Spencer HC, Wernsdorfer WH: The epide-
miology of malaria and its measurement.  In Malaria, principles
and practice of Malariology Edinburgh: Churchill Livingstone;
1988:999-1090. 